5.09
-0.0936(-1.81%)
Currency In USD
| Previous Close | 5.18 |
| Open | 5.17 |
| Day High | 5.17 |
| Day Low | 5.03 |
| 52-Week High | 41.22 |
| 52-Week Low | 4.7 |
| Volume | 34,739 |
| Average Volume | 230,332 |
| Market Cap | 12.82M |
| PE | -0.39 |
| EPS | -12.93 |
| Moving Average 50 Days | 6.23 |
| Moving Average 200 Days | 10.76 |
| Change | -0.09 |
If you invested $1000 in Imunon, Inc. (IMNN) 10 years ago, it would be worth $0.97 as of September 30, 2025 at a share price of $5.086. Whereas If you bought $1000 worth of Imunon, Inc. (IMNN) shares 5 years ago, it would be worth $30.97 as of September 30, 2025 at a share price of $5.086.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
GlobeNewswire Inc.
Sep 22, 2025 12:05 PM GMT
Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment Pivotal Phase 3 trial of IMNN-001 underway, with four trial sites activ
IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research
GlobeNewswire Inc.
Sep 19, 2025 12:05 PM GMT
OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-m
IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 02, 2025 12:05 PM GMT
LAWRENCEVILLE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a pre-recorded presentation from the Company will be avai